Case Report – Glioblastoma Cured with DCA Therapy
- 31 year old female with grade III astrocytoma transformed to glioblastoma
- treated with tumour debulking surgery and standard course of low dose chemo combined with radiation
- patient refused monthly high dose temozolomide chemo
- prognosis for survival with maximal standard therapy (surgery + chemo + radiation) is 12 – 18 months
- without monthly temozolomide chemo, prognosis is shorter
- treated by Dr. Khan with DCA + neuropathy prevention supplements
- MRI immediately after DCA therapy looked like treatment failure (cancer growth) but patient felt well
- diagnosed as pseudo-progression (false growth) which is typically cause by a strong anti-cancer immune response
- eventually MRI showed clearance of tumour
- patient remains alive and well 12 years after completion of therapy
- this case was published as a poster and presented at the Tripping Over the Truth metabolic cancer conference in Baltimore in 2017
This is an educational case report of a patient treated at Medicor. Every case is unique, not all patients achieve cancer reduction or remission with therapy. Case reports are not meant to imply a guarantee of specific results, but to illustrate what is possible with our cancer therapy protocols.
Was the patient idh mutant? Was the MGMT methylated? I understand that DCA may not work as well for idh mutant patients because it has a different metabolism than idh wildtype . Your comments are welcomed.
We do not collect stats on gene mutations for DCA-treated patients.
IDH mutation does not mean that DCA won’t work. Also, we no longer target glycolysis alone (we also target glutamine). That makes IDH mutation less relevant.